Global Solid Tumors Drugs Market 2016-2020 - Product Image

Global Solid Tumors Drugs Market 2016-2020

  • ID: 3775963
  • Report
  • Region: Global
  • 156 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Cold Genesys
  • Fortress Biotech
  • MedImmune
  • Oxford Biotherapeutics
  • MORE
About the Solid Tumors Drugs Market

The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.

Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.

The analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Novartis
- Celgene
- Johnson & Johnson
- Pfizer
- BMS

Other prominent vendors
- AbbVie
- AbGenomics
- ADC Therapeutics
- Advantagene
- Agensys
- Almac Group
- Ambrx
- Argos Therapeutics
- Array BioPharma
- Astellas Pharma
- AstraZeneca
- Bayer
- Biogen
- Biotech Pharmaceutical
- Boehringer Ingelheim
- Boston Biomedical
- Celldex Therapeutics
- Chugai Pharmaceutical
- Cold Genesys
- CTI BioPharma
- Daiichi Sankyo
- DNAtrix
- Ds-Pharma
- Eleison Pharmaceuticals
- Eli Lilly
- Endo Pharmaceuticals
- Formation Biologics
- Fortress Biotech
- Genmab
- GSK
- Immatics Biotechnologies
- Immunogen
- Immunomedics
- Intas Pharmaceuticals
- Kairos Therapeutics
- Kyowa Hakko Kirin
- MedImmune
- Merck
- Mersana Therapeutics
- Morphotek
- Neovii Biotech
- NewLink Genetics
- Northwest Biotherapeutics
- Novartis
- OncoMed Pharmaceuticals
- Oxford Biotherapeutics
- Peregrine Pharmaceuticals
- Polaris Pharmaceuticals
- Sanofi
- Seattle Genetics
- Spectrum Pharmaceuticals
- Stemcentrx
- Synthon Biopharmaceuticals
- TG Therapeutics
- XBiotech

Market drivers
- Exposure to risk factors
- For a full, detailed list, view the full report

Market challenges
- Patent expiration of top-selling drugs
- For a full, detailed list, view the full report

Market trends
- Emergence of targeted and combination therapies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Cold Genesys
  • Fortress Biotech
  • MedImmune
  • Oxford Biotherapeutics
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Assumptions
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Markers used for diagnosis of solid tumors
PART 05: Cost analysis

PART 06: Pipeline portfolio
  • Anticipated number of products with single and multiple indications by 2020
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by molecule type
  • Small molecules
  • Biologics
PART 09: Market segmentation by type of therapy
  • Chemotherapy
  • Hormone therapy
  • Targeted therapy
  • Immunotherapy
PART 10: Market segmentation by disease
  • Global breast cancer drugs market
  • Global NHL drugs market
  • Global colorectal cancer drugs market
  • Global NSCLC drugs market
  • Global prostate cancer drugs market
  • Global kidney cancer drugs market
  • Global retinoblastoma drugs market
  • Global cervical cancer market
  • Global melanoma drugs market
  • Global gastric cancer drugs market
  • Global pancreatic cancer drugs market
  • Global ovarian cancer drugs market
  • Global liver cancer drugs market
  • Global HL drugs market
  • Global glioblastoma multiforme drugs market
PART 11: Geographical segmentation
  • Solid tumors drugs market in Americas
  • Solid tumors drugs market in EMEA
  • Solid tumors drugs market in APAC
PART 12: Market drivers
  • Patient assistance programs
  • Exposure to risk factors
  • Provision for rare diseases
  • Promising pipeline
  • Increase in prevalence of solid tumors
PART 13: Impact of drivers

PART 14: Market challenges
  • Patent expiration of top-selling drugs
  • Poor diagnosis and screening
  • High cost of drugs
  • Availability of chemotherapy and off-label drugs
  • Stringent regulations
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Increase in cancer awareness
  • Emergence of targeted and combination therapies
  • Emergence of biosimilars
  • Joint ventures and
PARTnerships for R&D
  • Increase in use of brachytherapy
PART 17: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • F. Hoffmann-La Roche
  • Novartis
  • Celgene
  • Johnson & Johnson
  • Pfizer
  • BMS
  • Other prominent vendors
PART 18: Appendix
  • List of abbreviations
PART 19: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Types of solid tumors
Exhibit 03: Markers used for types of solid tumors
Exhibit 04: Annual treatment cost per patient for solid tumor drugs 2014
Exhibit 05: Average cost of surgeries associated with solid tumors 2014 ($)
Exhibit 06: Average cost of chemotherapy 2014 ($)
Exhibit 07: Average cost of radiation therapy 2014 ($)
Exhibit 08: Phase III pipeline molecules for solid tumors
Exhibit 09: Phase II pipeline molecules for solid tumors
Exhibit 10: Phase I pipeline molecules for solid tumors
Exhibit 11: Pre-clinical pipeline molecules for solid tumors
Exhibit 12: Pipeline share of solid tumors drugs 2015
Exhibit 13: Near-launch immuno-oncology pipeline assets 2020
Exhibit 14: Global solid tumors market 2015-2020 ($ billions)
Exhibit 15: Factors influencing global solid tumors drugs market 2015
Exhibit 16: Five forces analysis
Exhibit 17: Segmentation of global solid tumors drugs market by type of molecules 2015
Exhibit 18: Market segmentation by disease
Exhibit 19: Global solid tumors drugs market: Segmentation by disease 2015
Exhibit 20: Global solid tumors drugs market: YoY revenue and growth based on drug class 2015-2020 ($ billions)
Exhibit 21: Stages of breast cancer based on tumor size and extent of metastasis
Exhibit 22: Classification of breast cancer based on genetic makeup of tumor cells
Exhibit 23: Treatment regimen for breast cancer
Exhibit 24: Product offerings for breast cancer drugs market
Exhibit 25: Global breast cancer drugs market 2015-2020 ($ billions)
Exhibit 26: Product offerings for global NHL drugs market
Exhibit 27: Global NHL drugs market 2015-2020 ($ billions)
Exhibit 28: Product offerings for global colorectal cancer drugs market
Exhibit 29: Global colorectal cancer drugs market 2015-2020 ($ billions)
Exhibit 30: Products offerings for global NSCLC drugs market
Exhibit 31: Global NSCLC drugs market 2015-2020 ($ billions)
Exhibit 32: Product offerings for global prostate cancer drugs market
Exhibit 33: Global prostate cancer drugs market 2015-2020 ($ billions)
Exhibit 34: Product offerings for global kidney cancer drugs market
Exhibit 35: Global kidney cancer drugs market 2015-2020 ($ billions)
Exhibit 36: Product offerings for global retinoblastoma drugs market
Exhibit 37: Global retinoblastoma drugs market 2015-2020 ($ billions)
Exhibit 38: Product offerings for global cervical cancer market
Exhibit 39: Global cervical cancer market 2015-2020 ($ billions)
Exhibit 40: Product offerings for global melanoma drugs market
Exhibit 41: Global melanoma drugs market 2015-2020 ($ billions)
Exhibit 42: Products offerings for global gastric cancer drugs market
Exhibit 43: Global gastric cancer drugs market 2015-2020 ($ billions)
Exhibit 44: Products offerings for global pancreatic cancer drugs market
Exhibit 45: Global pancreatic cancer drugs market 2015-2020 ($ billions)
Exhibit 46: Products offerings for global ovarian cancer drugs market
Exhibit 47: Global ovarian cancer drugs market 2015-2020 ($ billions)
Exhibit 48: Product offerings for global liver cancer drugs market
Exhibit 49: Global liver cancer drugs market 2015-2020 ($ billions)
Exhibit 50: Products offerings for global HL drugs market
Exhibit 51: Global HL drugs market 2015-2020 ($ millions)
Exhibit 52: Products offerings for global glioblastoma multiforme drugs market
Exhibit 53: Global glioblastoma multiforme drugs market 2015-2020 ($ millions)
Exhibit 54: Global solid tumors drugs market by geography 2015
Exhibit 55: Global solid tumors drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 56: Global solid tumors drugs market revenue by geography 2015-2020
Exhibit 57: Solid tumors drugs market in Americas 2015-2020 ($ billions)
Exhibit 58: Solid tumors drugs market in EMEA 2015-2020 ($ billions)
Exhibit 59: Solid tumors drugs market in APAC 2015-2020 ($ billions)
Exhibit 60: Global solid tumors drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 61: Global incidence of solid tumor types 2015
Exhibit 62: Global mortality of solid tumor types 2015
Exhibit 63: Impact of drivers
Exhibit 64: Patent expiries of major cancer monoclonal antibodies by 2020
Exhibit 65: Average cost comparison of Herceptin 2014
Exhibit 66: Impact of drivers and challenges
Exhibit 67: Expected combination regimen launches in oncology
Exhibit 68: YoY Sales comparison of top drugs 2013-2015 ($ billions)
Exhibit 69: Ranking of major vendors for global solid tumors drugs market
Exhibit 70: Market share analysis of global solid tumors drugs market 2015
Exhibit 71: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indications) 2013-2015 ($ billions)
Exhibit 72: MabThera/Rituxan geographic segmentation by revenue 2015
Exhibit 73: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 74: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 76: F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
Exhibit 77: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 78: F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
Exhibit 79: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 80: F. Hoffmann-La Roche: Geographical segmentation of Kadycla 2015
Exhibit 81: F. Hoffmann-La Roche: Revenue generated from net product sales of Tarceva 2013-2015 ($ billions)
Exhibit 82: F. Hoffmann-La Roche: Geographical segmentation of Tarceva 2015
Exhibit 83: F. Hoffmann-La Roche: Key takeaways
Exhibit 84: Novartis: YoY revenue and growth rate of Gleevec 2013-2015 ($ billions)
Exhibit 85: Novartis: YoY revenue and growth rate of Sandostatin 2013-2015 ($ billions)
Exhibit 86: Novartis: YoY revenue and growth rate of Sandostatin 2013-2015 ($ billions)
Exhibit 87: Novartis: Key takeaways
Exhibit 88: Celgene: YoY revenue and growth rate of Revlimid 2013-2015 ($ billions)
Exhibit 89: Celgene: YoY revenue and growth rate of Abraxane 2013-2015 ($ millions)
Exhibit 90: Celgene: YoY revenue and growth rate of Istodax 2013-2015 ($ millions)
Exhibit 91: Celgene: YoY revenue and growth rate of Pomalyst 2013-2015 ($ millions)
Exhibit 92: Celgene: YoY revenue and growth rate of Pomalyst 2013-2015 ($ millions)
Exhibit 93: Celgene: Key takeaways
Exhibit 94: Johnson & Johnson: YoY revenue comparison of Zytiga 2013-2015 ($ billions)
Exhibit 95: Johnson & Johnson: YoY revenue comparison of Velcade 2013-2015 ($ billions)
Exhibit 96: Johnson & Johnson: YoY revenue comparison of Imbruvica 2014-2015 ($ millions)
Exhibit 97: Key takeaways
Exhibit 98: Pfizer: YoY revenue and growth rate of Sutent 2013-2015 ($ billions)
Exhibit 99: Pfizer: YoY revenue and growth rate of Xalkori 2013-2015 ($ millions)
Exhibit 100: Pfizer: YoY revenue and growth rate of Inlyta 2013-2015 ($ millions)
Exhibit 101: Key takeaways
Exhibit 102: BMS: YoY revenue and growth rate of Erbitux 2013-2015 ($ millions)
Exhibit 103: BMS: YoY revenue and growth rate of Sprycel 2013-2015 ($ billions)
Exhibit 104: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Cold Genesys
  • Fortress Biotech
  • MedImmune
  • Oxford Biotherapeutics
  • MORE
New Report Released: – Global Solid Tumors Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the global solid tumors drugs market: F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, and BMS.

Other Prominent Vendors in the market are: AbbVie, AbGenomics, ADC Therapeutics, Advantagene, Agensys, Almac Group, Ambrx, Argos Therapeutics, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer Ingelheim, Boston Biomedical, Celldex Therapeutics, Chugai Pharmaceutical, Cold Genesys, CTI BioPharma, Daiichi Sankyo, DNAtrix, Ds-Pharma, Eleison Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals, Formation Biologics, Fortress Biotech, Genmab, GSK, Immatics Biotechnologies, Immunogen, Immunomedics, Intas Pharmaceuticals, Kairos Therapeutics, Kyowa Hakko Kirin, MedImmune, Merck, Mersana Therapeutics, Morphotek, Neovii Biotech, NewLink Genetics, Northwest Biotherapeutics, Novartis, OncoMed Pharmaceuticals, Oxford Biotherapeutics, Peregrine Pharmaceuticals, Polaris Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, Stemcentrx, Synthon Biopharmaceuticals, TG Therapeutics, and XBiotech.

Commenting on the report, an analyst from the research team said: “A trend which is helping to boost market growth is the emergence of targeted and combination therapies. Targeted and combination therapies are being increasingly developed to treat solid tumors. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2, wherein drugs such as Kadcyla and Herceptin are administered as monotherapies or in combination. Targeting multiple pathways are known to reduce the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating solid tumors.”

According to the report, a key growth driver which is helping to boost market growth is the exposure to risk factors. Exposure to risk factors for solid tumors and the decrease in practices that reduce this risk are expected to increase the incidence of solid tumors. Solid tumors are associated with modifiable risk factors such as alcohol consumption, physical inactivity, weight gain, and obesity.

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer. The consumption of three to six glasses of alcoholic drinks per week can increase the risk of developing the disease by 15%. Also, women with estrogen-positive breast cancer who consume one glass of any alcoholic drink per day have a 90% higher risk of developing second cancer.

Further, the report states that one challenge that could hamper market growth is the patent expiration on top-selling drugs. The patent rights of most cancer drugs either have expired or are nearing their expiry date. As a result, inexpensive generic drugs are being introduced in the market. These drugs may increase the competition in the market, eventually reducing the price of key drugs. Also, patent expiries often result in loss of market exclusivity, decreasing the sales of the branded product.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- F Hoffmann-La Roche
- Novartis
- Celgene
- Johnson & Johnson
- Pfizer
- BMS
- AbbVie
- AbGenomics
- ADC Therapeutics
- Advantagene
- Agensys
- Almac Group
- Ambrx
- Argos Therapeutics
- Array BioPharma
- Astellas Pharma
- AstraZeneca
- Bayer
- Biogen
- Biotech Pharmaceutical
- Boehringer Ingelheim
- Boston Biomedical
- Celldex Therapeutics
- Chugai Pharmaceutical
- Cold Genesys
- CTI BioPharma
- Daiichi Sankyo
- DNAtrix
- Ds-Pharma
- Eleison Pharmaceuticals
- Eli Lilly
- Endo Pharmaceuticals
- Formation Biologics
- Fortress Biotech
- Genmab
- GSK
- Immatics Biotechnologies
- Immunogen
- Immunomedics
- Intas Pharmaceuticals
- Kairos Therapeutics
- Kyowa Hakko Kirin
- MedImmune
- Merck
- Mersana Therapeutics
- Morphotek
- Neovii Biotech
- NewLink Genetics
- Northwest Biotherapeutics
- Novartis
- OncoMed Pharmaceuticals
- Oxford Biotherapeutics
- Peregrine Pharmaceuticals
- Polaris Pharmaceuticals
- Sanofi
- Seattle Genetics
- Spectrum Pharmaceuticals
- Stemcentrx
- Synthon Biopharmaceuticals
- TG Therapeutics
- XBiotech
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll